Biomerica Gains Vietnam Approval for Colorectal Cancer Screening Test
Event summary
- Vietnam’s Hanoi Department of Health approved Biomerica’s EZ Detect™ for nationwide distribution on February 18, 2026.
- EZ Detect™ is an FDA-cleared, two-minute at-home test for early detection of colorectal cancer.
- Biomerica partners with a major healthcare distributor in Vietnam for sales through pharmacies, hospitals, and online channels.
- Colorectal cancer is the fourth most common cancer in Vietnam, with a 45% five-year survival rate, significantly lower than the 91% in the U.S.
The big picture
Biomerica’s approval in Vietnam marks its strategic entry into Southeast Asia’s rapidly growing healthcare market, addressing a critical public health need. The region’s rising healthcare spending and aging population present a significant opportunity for early detection solutions like EZ Detect™. This approval could serve as a template for expansion into other high-need markets, potentially saving lives and reducing late-stage cancer treatment costs.
What we're watching
- Market Expansion
- Whether Biomerica can replicate this success in other Southeast Asian markets.
- Regulatory Dynamics
- The pace at which other countries approve EZ Detect™ for distribution.
- Competitive Positioning
- How EZ Detect™ differentiates itself from traditional fecal occult blood tests in patient compliance and early detection.
Related topics